| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antifungal drug susceptibility testing and resistance in Aspergillus
|
Warnock, David W.
|
|
1999
|
21-22 |
5 |
p. 326-334
9 p.
|
artikel
|
| 2 |
Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype
|
Henderson, Clare
|
|
2003
|
21-22 |
5 |
p. 247-256
10 p.
|
artikel
|
| 3 |
Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis ?
|
Kaneshiro, Edna S.
|
|
2001
|
21-22 |
5 |
p. 322-329
8 p.
|
artikel
|
| 4 |
Atovaquone resistance in malaria parasites
|
Vaidya, Akhil B
|
|
2000
|
21-22 |
5 |
p. 283-287
5 p.
|
artikel
|
| 5 |
Breast cancer response to paclitaxel in vivo
|
Symmans, Fraser W.
|
|
2001
|
21-22 |
5 |
p. 297-302
6 p.
|
artikel
|
| 6 |
cDNA Technologies and their application to drug resistance research: power, potential and problems
|
Duan, Zhenfeng
|
|
2000
|
21-22 |
5 |
p. 277-282
6 p.
|
artikel
|
| 7 |
Cellular survival pathways and resistance to cancer therapy
|
Dennis, Phillip A.
|
|
1998
|
21-22 |
5 |
p. 301-309
9 p.
|
artikel
|
| 8 |
Cell wall targets in methicillin-resistant staphylococci
|
Labischinski, Harald
|
|
1999
|
21-22 |
5 |
p. 319-325
7 p.
|
artikel
|
| 9 |
Clinical cancer research 2002: new agents and therapies
|
Gietema, J.A
|
|
2002
|
21-22 |
5 |
p. 192-203
12 p.
|
artikel
|
| 10 |
Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far
|
Kontoyiannis, Dimitrios P.
|
|
2003
|
21-22 |
5 |
p. 257-269
13 p.
|
artikel
|
| 11 |
Drug resistance in ovarian cancer: The emerging importance of gene transcription and spatio-temporal regulation of resistance
|
Richardson, Alan
|
|
2005
|
21-22 |
5 |
p. 311-321
11 p.
|
artikel
|
| 12 |
Drug transport and drug resistance in African trypanosomes
|
Mäser, Pascal
|
|
2003
|
21-22 |
5 |
p. 281-290
10 p.
|
artikel
|
| 13 |
Editorial Board
|
|
|
2002
|
21-22 |
5 |
p. i-
1 p.
|
artikel
|
| 14 |
Editorial Board
|
|
|
2003
|
21-22 |
5 |
p. i-
1 p.
|
artikel
|
| 15 |
Editorial Board
|
|
|
2005
|
21-22 |
5 |
p. i-
1 p.
|
artikel
|
| 16 |
Erratum
|
Stöhr, Klaus
|
|
2000
|
21-22 |
5 |
p. 313-
1 p.
|
artikel
|
| 17 |
Erratum to “Strategies to target HER2/neu overexpression for cancer therapy”
|
Chen, Jin-Shing
|
|
2003
|
21-22 |
5 |
p. 295-296
2 p.
|
artikel
|
| 18 |
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells
|
Roninson, Igor B.
|
|
2001
|
21-22 |
5 |
p. 303-313
11 p.
|
artikel
|
| 19 |
Infectious disease 2000: drug resistance and new drugs
|
Georgopapadakou, Nafsika H.
|
|
2000
|
21-22 |
5 |
p. 265-269
5 p.
|
artikel
|
| 20 |
Infectious disease 2001: drug resistance, new drugs
|
Georgopapadakou, Nafsika H
|
|
2002
|
21-22 |
5 |
p. 181-191
11 p.
|
artikel
|
| 21 |
Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives
|
Dermond, Olivier
|
|
2001
|
21-22 |
5 |
p. 314-321
8 p.
|
artikel
|
| 22 |
Insights into oxazaphosphorine resistance and possible approaches to its circumvention
|
Zhang, Jing
|
|
2005
|
21-22 |
5 |
p. 271-297
27 p.
|
artikel
|
| 23 |
Is there a role for glyoxalase I inhibitors as antitumor drugs?
|
Tew, Kenneth D.
|
|
2000
|
21-22 |
5 |
p. 263-264
2 p.
|
artikel
|
| 24 |
Liposome-based approaches to overcome anticancer drug resistance
|
Mamot, Christoph
|
|
2003
|
21-22 |
5 |
p. 271-279
9 p.
|
artikel
|
| 25 |
Literature highlights:Recent research in infectious disease drug resistance(6/5)
|
|
|
2003
|
21-22 |
5 |
p. 291-293
3 p.
|
artikel
|
| 26 |
Literature highlights: recent research in infectious disease drug resistance
|
|
|
2005
|
21-22 |
5 |
p. 331-338
8 p.
|
artikel
|
| 27 |
MEETINGS CALENDAR
|
|
|
2001
|
21-22 |
5 |
p. 331-333
3 p.
|
artikel
|
| 28 |
Meetings calendar
|
|
|
1998
|
21-22 |
5 |
p. 343-344
2 p.
|
artikel
|
| 29 |
Meetings Calendar
|
|
|
1999
|
21-22 |
5 |
p. 341-344
4 p.
|
artikel
|
| 30 |
Meetings Calendar
|
|
|
2000
|
21-22 |
5 |
p. 315-317
3 p.
|
artikel
|
| 31 |
Mismatch repair and drug responses in cancer
|
Sedwick, W.David
|
|
1999
|
21-22 |
5 |
p. 295-306
12 p.
|
artikel
|
| 32 |
Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa
|
Land, Kirkwood M.
|
|
1999
|
21-22 |
5 |
p. 289-294
6 p.
|
artikel
|
| 33 |
New physiological functions for drug-transporting P-glycoproteins?
|
Borst, P.
|
|
1998
|
21-22 |
5 |
p. 337-339
3 p.
|
artikel
|
| 34 |
Nucleoside transport and its significance for anticancer drug resistance
|
Mackey, John R.
|
|
1998
|
21-22 |
5 |
p. 310-324
15 p.
|
artikel
|
| 35 |
Origins of the aminoglycoside modifying enzymes
|
Rather, Philip N.
|
|
1998
|
21-22 |
5 |
p. 285-291
7 p.
|
artikel
|
| 36 |
p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53
|
Fojo, Tito
|
|
2002
|
21-22 |
5 |
p. 209-216
8 p.
|
artikel
|
| 37 |
Potential drug targets in cyst-wall biosynthesis by intestinal protozoa
|
Jarroll, Edward L.
|
|
2003
|
21-22 |
5 |
p. 239-246
8 p.
|
artikel
|
| 38 |
Redox-sensitive signaling factors as a novel molecular targets for cancer therapy
|
Pennington, J. Daniel
|
|
2005
|
21-22 |
5 |
p. 322-330
9 p.
|
artikel
|
| 39 |
Resistance to epidermal growth factor receptor-targeted therapy
|
Morgillo, Floriana
|
|
2005
|
21-22 |
5 |
p. 298-310
13 p.
|
artikel
|
| 40 |
Resistance to imatinib (Glivec): update on clinical mechanisms
|
Weisberg, Ellen
|
|
2003
|
21-22 |
5 |
p. 231-238
8 p.
|
artikel
|
| 41 |
Role of fem factors in methicillin resistance
|
Berger-Bächi, Brigitte
|
|
1998
|
21-22 |
5 |
p. 325-335
11 p.
|
artikel
|
| 42 |
Small cell and its stroma: determinant of pan-resistance?
|
Sehested, Maxwell
|
|
1999
|
21-22 |
5 |
p. 281-283
3 p.
|
artikel
|
| 43 |
The impact of antibiotic use on resistance development and persistence
|
Barbosa, Teresa M.
|
|
2000
|
21-22 |
5 |
p. 303-311
9 p.
|
artikel
|
| 44 |
The (patho)physiological functions of the MRP family
|
Renes, Johan
|
|
2000
|
21-22 |
5 |
p. 289-302
14 p.
|
artikel
|
| 45 |
The question begs — what is the role of P-glycoprotein in normal physiology?
|
Johnstone, Ricky W.
|
|
1998
|
21-22 |
5 |
p. 340-342
3 p.
|
artikel
|
| 46 |
The role of caspase-8 in resistance to cancer chemotherapy
|
Kim, Peter K.M.
|
|
2001
|
21-22 |
5 |
p. 293-296
4 p.
|
artikel
|
| 47 |
The tumor microenvironment as a determinant of drug response and resistance
|
Dalton, William S.
|
|
1999
|
21-22 |
5 |
p. 285-288
4 p.
|
artikel
|
| 48 |
39thInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, USA, 26–29 September 1999
|
Georgopapadakou, Nafsika H.
|
|
1999
|
21-22 |
5 |
p. 335-340
6 p.
|
artikel
|
| 49 |
Topoisomerase I inhibitors: selectivity and cellular resistance
|
Pommier, Yves
|
|
1999
|
21-22 |
5 |
p. 307-318
12 p.
|
artikel
|
| 50 |
Tumor necrosis factor: clinical use and mechanisms of action
|
Rüegg, Curzio
|
|
2000
|
21-22 |
5 |
p. 271-276
6 p.
|
artikel
|
| 51 |
Tumor senescence as a determinant of drug response in vivo
|
Roninson, Igor B
|
|
2002
|
21-22 |
5 |
p. 204-208
5 p.
|
artikel
|
| 52 |
Virological and clinical implications of resistance to HIV-1 protease inhibitors
|
Condra, Jon H.
|
|
1998
|
21-22 |
5 |
p. 292-299
8 p.
|
artikel
|
| 53 |
Virus-mediated killing of cells that lack p53 activity
|
Nemunaitis, John
|
|
2001
|
21-22 |
5 |
p. 289-291
3 p.
|
artikel
|
Tijdschrift beschrijving